Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Dexcom Inc (DXCM) since 2014 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Dexcom Inc. (See page 1 of this report.) Table 2 shows the detailed insider transactions. This company's CIK number is 1093557.
Total stock buying since 2014: $2,751,008.
Total stock sales since 2014: $791,825,722.
Total stock option exercises since 2014: $16,751,908.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2026 | 0 | $0 | 76,162 | $5,450,794 | 0 | $0 |
| 2025 | 18,200 | $1,004,658 | 187,441 | $14,488,585 | 0 | $0 |
| 2024 | 0 | $0 | 290,565 | $37,445,869 | 0 | $0 |
| 2023 | 0 | $0 | 239,577 | $27,218,371 | 0 | $0 |
| 2022 | 0 | $0 | 76,614 | $22,696,065 | 0 | $0 |
| 2021 | 0 | $0 | 299,457 | $128,341,957 | 0 | $0 |
| 2020 | 0 | $0 | 438,604 | $143,140,207 | 20,385 | $199,543 |
| 2019 | 0 | $0 | 427,888 | $64,727,520 | 30,603 | $153,065 |
| 2018 | 0 | $0 | 576,502 | $64,666,028 | 197,834 | $1,158,125 |
| 2017 | 35,000 | $1,746,350 | 364,657 | $27,002,321 | 208,503 | $1,718,699 |
| 2016 | 0 | $0 | 1,234,804 | $98,963,335 | 387,003 | $2,212,500 |
| 2015 | 0 | $0 | 2,059,653 | $157,458,815 | 1,352,001 | $11,309,976 |
| 2014 | 0 | $0 | 7,500 | $225,855 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2015-05-07 | Gregg Terrance H (Executive Chairman) | Sale | 40,000 | 67.52 | 2,700,920 |
| 2015-05-07 | Gregg Terrance H (Executive Chairman) | Option Ex | 40,000 | 6.33 | 253,200 |
| 2015-05-04 | Balo Andrew K (EVP, Clinical, Regulatory) | Sale | 7,500 | 67.99 | 509,902 |
| 2015-05-04 | Balo Andrew K (EVP, Clinical, Regulatory) | Option Ex | 7,500 | 9.80 | 73,500 |
| 2015-05-04 | Sayer Kevin R (President & CEO) | Sale | 25,000 | 68.01 | 1,700,325 |
| 2015-05-04 | Gregg Terrance H (Executive Chairman) | Sale | 20,000 | 68.06 | 1,361,279 |
| 2015-05-04 | Gregg Terrance H (Executive Chairman) | Option Ex | 20,000 | 8.95 | 179,000 |
| 2015-04-30 | Gregg Terrance H (Executive Chairman) | Sale | 14,250 | 67.13 | 956,602 |
| 2015-04-28 | Moy Jeffrey (SVP, Operations) | Sale | 5,000 | 67.55 | 337,750 |
| 2015-04-27 | Moy Jeffrey (SVP, Operations) | Sale | 5,000 | 69.27 | 346,370 |
| 2015-04-27 | Moy Jeffrey (SVP, Operations) | Option Ex | 5,000 | 9.36 | 46,800 |
| 2015-04-23 | Pacelli Steven Robert (EVP, Strategy & Corp. Dev.) | Sale | 14,000 | 69.84 | 977,718 |
| 2015-04-23 | Pacelli Steven Robert (EVP, Strategy & Corp. Dev.) | Option Ex | 14,000 | 7.79 | 109,060 |
| 2015-04-23 | Balo Andrew K (EVP, Clinical, Regulatory) | Sale | 7,500 | 69.65 | 522,352 |
| 2015-04-23 | Balo Andrew K (EVP, Clinical, Regulatory) | Option Ex | 7,500 | 9.80 | 73,500 |
| 2015-04-21 | Pacelli Steven Robert (EVP, Strategy & Corp. Dev.) | Sale | 25,709 | 69.52 | 1,787,289 |
| 2015-04-21 | Pacelli Steven Robert (EVP, Strategy & Corp. Dev.) | Option Ex | 25,709 | 20.65 | 530,890 |
| 2015-04-20 | Roper Jess (SVP, CFO) | Sale | 7,000 | 68.03 | 476,238 |
| 2015-04-20 | Roper Jess (SVP, CFO) | Option Ex | 6,000 | 7.63 | 45,780 |
| 2015-04-15 | Gregg Terrance H (Executive Chairman) | Sale | 15,000 | 67.56 | 1,013,415 |
| 2015-04-14 | Moy Jeffrey (SVP, Operations) | Sale | 5,000 | 67.32 | 336,584 |
| 2015-04-13 | Moy Jeffrey (SVP, Operations) | Sale | 5,000 | 67.78 | 338,905 |
| 2015-04-13 | Moy Jeffrey (SVP, Operations) | Option Ex | 5,000 | 9.36 | 46,800 |
| 2015-04-10 | Moy Jeffrey (SVP, Operations) | Sale | 10,766 | 65.77 | 708,036 |
| 2015-04-10 | Moy Jeffrey (SVP, Operations) | Option Ex | 10,766 | 9.04 | 97,303 |
| 2015-04-09 | Pacelli Steven Robert (EVP, Strategy & Corp. Dev.) | Sale | 20,000 | 65.03 | 1,300,560 |
| 2015-04-09 | Pacelli Steven Robert (EVP, Strategy & Corp. Dev.) | Option Ex | 20,000 | 15.99 | 319,800 |
| 2015-04-09 | Valdes Jorge A (CTO) | Sale | 11,440 | 64.78 | 741,128 |
| 2015-04-09 | Balo Andrew K (EVP, Clinical, Regulatory) | Sale | 7,500 | 64.55 | 484,147 |
| 2015-04-09 | Balo Andrew K (EVP, Clinical, Regulatory) | Option Ex | 7,500 | 9.80 | 73,500 |
| 2015-04-08 | Lister John (Sr. VP, General Counsel) | Sale | 5,039 | 63.84 | 321,679 |
| 2015-04-08 | Lister John (Sr. VP, General Counsel) | Option Ex | 5,039 | 8.85 | 44,595 |
| 2015-04-08 | Valdes Jorge A (CTO) | Sale | 8,244 | 63.81 | 526,049 |
| 2015-04-08 | Valdes Jorge A (CTO) | Option Ex | 8,244 | 13.45 | 110,881 |
| 2015-03-25 | Balo Andrew K (EVP, Clinical, Regulatory) | Sale | 7,500 | 61.05 | 457,852 |
| 2015-03-25 | Balo Andrew K (EVP, Clinical, Regulatory) | Option Ex | 7,500 | 9.80 | 73,500 |
| 2015-03-23 | Doubleday Richard (EVP, Chief Commercial Officer) | Sale | 4,000 | 61.25 | 244,992 |
| 2015-03-23 | Doubleday Richard (EVP, Chief Commercial Officer) | Option Ex | 4,000 | 6.03 | 24,120 |
| 2015-03-23 | Pacelli Steven Robert (EVP, Strategy & Corp. Dev.) | Sale | 14,000 | 61.33 | 858,676 |
| 2015-03-23 | Pacelli Steven Robert (EVP, Strategy & Corp. Dev.) | Option Ex | 14,000 | 7.79 | 109,060 |
| 2015-03-20 | Valdes Jorge A (CTO) | Sale | 27,100 | 62.32 | 1,688,872 |
| 2015-03-18 | Roper Jess (SVP, CFO) | Sale | 7,000 | 62.41 | 436,863 |
| 2015-03-18 | Roper Jess (SVP, CFO) | Option Ex | 6,000 | 7.63 | 45,780 |
| 2015-03-17 | Gregg Terrance H (Executive Chairman) | Sale | 15,000 | 62.82 | 942,300 |
| 2015-03-13 | Skyler Jay S (Director) | Sale | 16,500 | 60.01 | 990,231 |
| 2015-03-13 | Skyler Jay S (Director) | Option Ex | 16,500 | 21.09 | 348,067 |
| 2015-03-12 | Doubleday Richard (EVP, Chief Commercial Officer) | Sale | 20,000 | 59.11 | 1,182,180 |
| 2015-03-12 | Doubleday Richard (EVP, Chief Commercial Officer) | Option Ex | 20,000 | 9.80 | 196,000 |
| 2015-03-12 | Valdes Jorge A (CTO) | Sale | 11,138 | 59.78 | 665,829 |
| 2015-03-12 | Skyler Jay S (Director) | Sale | 6,936 | 60.00 | 416,160 |
| 2015-03-12 | Skyler Jay S (Director) | Option Ex | 6,936 | 16.19 | 112,293 |
| 2015-03-11 | Balo Andrew K (EVP, Clinical, Regulatory) | Sale | 7,500 | 58.58 | 439,365 |
| 2015-03-11 | Balo Andrew K (EVP, Clinical, Regulatory) | Option Ex | 7,500 | 9.80 | 73,500 |
| 2015-03-11 | Skyler Jay S (Director) | Sale | 21,564 | 60.00 | 1,293,904 |
| 2015-03-11 | Skyler Jay S (Director) | Option Ex | 21,564 | 12.00 | 258,768 |
| 2015-03-09 | Lister John (Sr. VP, General Counsel) | Sale | 5,039 | 58.77 | 296,157 |
| 2015-03-09 | Lister John (Sr. VP, General Counsel) | Option Ex | 5,039 | 8.85 | 44,595 |
| 2015-03-09 | Valdes Jorge A (CTO) | Sale | 14,882 | 59.30 | 882,443 |
| 2015-03-09 | Valdes Jorge A (CTO) | Option Ex | 8,244 | 13.45 | 110,881 |
| 2015-03-05 | Kahn Barbara (Director) | Sale | 3,000 | 60.29 | 180,873 |
| 2015-03-02 | Moy Jeffrey (SVP, Operations) | Sale | 5,000 | 60.33 | 301,650 |
| 2015-03-02 | Moy Jeffrey (SVP, Operations) | Option Ex | 5,000 | 9.80 | 49,000 |
| 2015-02-24 | Balo Andrew K (EVP, Clinical, Regulatory) | Sale | 7,500 | 62.22 | 466,635 |
| 2015-02-24 | Balo Andrew K (EVP, Clinical, Regulatory) | Option Ex | 7,500 | 9.80 | 73,500 |
| 2015-02-23 | Doubleday Richard (EVP, Chief Commercial Officer) | Sale | 4,000 | 63.58 | 254,336 |
| 2015-02-23 | Doubleday Richard (EVP, Chief Commercial Officer) | Option Ex | 4,000 | 6.03 | 24,120 |
| 2015-02-23 | Pacelli Steven Robert (EVP, Strategy & Corp. Dev.) | Sale | 14,000 | 63.43 | 888,020 |
| 2015-02-23 | Pacelli Steven Robert (EVP, Strategy & Corp. Dev.) | Option Ex | 14,000 | 7.79 | 109,060 |
| 2015-02-18 | Roper Jess (SVP, CFO) | Sale | 7,000 | 61.87 | 433,097 |
| 2015-02-18 | Roper Jess (SVP, CFO) | Option Ex | 6,000 | 7.63 | 45,780 |
| 2015-02-17 | Moy Jeffrey (SVP, Operations) | Sale | 5,044 | 62.11 | 313,292 |
| 2015-02-17 | Moy Jeffrey (SVP, Operations) | Option Ex | 5,044 | 9.80 | 49,431 |
| 2015-02-17 | Gregg Terrance H (Executive Chairman) | Sale | 15,000 | 62.19 | 932,805 |
| 2015-02-10 | Balo Andrew K (EVP, Clinical, Regulatory) | Sale | 7,500 | 61.41 | 460,605 |
| 2015-02-10 | Balo Andrew K (EVP, Clinical, Regulatory) | Option Ex | 7,500 | 9.80 | 73,500 |
| 2015-02-09 | Lister John (Sr. VP, General Counsel) | Sale | 5,039 | 61.66 | 310,694 |
| 2015-02-09 | Lister John (Sr. VP, General Counsel) | Option Ex | 5,039 | 6.71 | 33,836 |
| 2015-02-09 | Valdes Jorge A (CTO) | Sale | 9,170 | 61.67 | 565,486 |
| 2015-02-09 | Valdes Jorge A (CTO) | Option Ex | 8,244 | 13.45 | 110,881 |
| 2015-02-02 | Moy Jeffrey (SVP, Operations) | Sale | 5,000 | 60.69 | 303,425 |
| 2015-02-02 | Moy Jeffrey (SVP, Operations) | Option Ex | 5,000 | 9.80 | 49,000 |
| 2015-01-26 | Pacelli Steven Robert (EVP, Strategy & Corp. Dev.) | Sale | 10,532 | 62.18 | 654,890 |
| 2015-01-26 | Pacelli Steven Robert (EVP, Strategy & Corp. Dev.) | Option Ex | 10,532 | 11.33 | 119,327 |
| 2015-01-26 | Balo Andrew K (EVP, Clinical, Regulatory &) | Sale | 15,001 | 59.24 | 888,734 |
| 2015-01-26 | Balo Andrew K (EVP, Clinical, Regulatory &) | Option Ex | 15,001 | 6.87 | 103,101 |
| 2015-01-23 | Doubleday Richard (EVP, Chief Commercial Officer) | Sale | 4,000 | 58.22 | 232,864 |
| 2015-01-23 | Doubleday Richard (EVP, Chief Commercial Officer) | Option Ex | 4,000 | 6.03 | 24,120 |
| 2015-01-23 | Pacelli Steven Robert (EVP, Strategy & Corp. Dev.) | Sale | 14,000 | 57.78 | 808,920 |
| 2015-01-23 | Pacelli Steven Robert (EVP, Strategy & Corp. Dev.) | Option Ex | 14,000 | 7.79 | 109,060 |
| 2015-01-20 | Moy Jeffrey (SVP, Operations) | Sale | 5,000 | 57.58 | 287,905 |
| 2015-01-20 | Moy Jeffrey (SVP, Operations) | Option Ex | 5,000 | 9.80 | 49,000 |
| 2015-01-20 | Roper Jess (SVP, CFO) | Sale | 7,000 | 57.33 | 401,303 |
| 2015-01-20 | Roper Jess (SVP, CFO) | Option Ex | 6,000 | 7.63 | 45,780 |
| 2015-01-15 | Gregg Terrance H (Executive Chairman) | Sale | 15,000 | 57.84 | 867,555 |
| 2015-01-13 | Pacelli Steven Robert (EVP, Strategy & Corp. Dev.) | Sale | 9,468 | 62.22 | 589,136 |
| 2015-01-13 | Pacelli Steven Robert (EVP, Strategy & Corp. Dev.) | Option Ex | 9,468 | 11.33 | 107,272 |
| 2015-01-12 | Pacelli Steven Robert (EVP, Strategy & Corp. Dev.) | Sale | 20,000 | 59.18 | 1,183,540 |
| 2015-01-12 | Pacelli Steven Robert (EVP, Strategy & Corp. Dev.) | Option Ex | 20,000 | 11.33 | 226,600 |
| 2015-01-09 | Valdes Jorge A (CTO) | Sale | 926 | 58.53 | 54,198 |
| 2015-01-08 | Lister John (Sr. VP, General Counsel) | Sale | 5,039 | 57.42 | 289,339 |
| 2015-01-08 | Lister John (Sr. VP, General Counsel) | Option Ex | 5,039 | 4.58 | 23,078 |
| 2015-01-08 | Valdes Jorge A (CTO) | Sale | 8,244 | 57.44 | 473,494 |
| 2015-01-08 | Valdes Jorge A (CTO) | Option Ex | 8,244 | 13.45 | 110,881 |
| 2015-01-05 | Moy Jeffrey (SVP, Operations) | Sale | 5,000 | 55.27 | 276,370 |
| 2015-01-05 | Moy Jeffrey (SVP, Operations) | Option Ex | 5,000 | 9.80 | 49,000 |
| 2014-05-08 | Kahn Barbara (Director) | Sale | 7,500 | 30.11 | 225,855 |
Insider trading activities including stock purchases, stock sales, and option exercises of DXCM listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Dexcom Inc (symbol DXCM, CIK number 1093557) see the Securities and Exchange Commission (SEC) website.